EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF ‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis

Mathieu Johnson, Sandra Turcotte iD

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.13770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Mathieu Johnson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Université de Moncton, Canada. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Histone-Lysine N-Methyltransferase, Kidney Neoplasms, DNA Damage. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation de la recherche en santé du Nouveau-Brunswick, New Brunswick Innovation Foundation, Canadian Cancer Society Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss of chromosome 3p and loss of heterogeneity of the von Hippel–Lindau ( VHL ) gene are common characteristics of clear cell renal cell carcinoma (ccRCC). Despite frequent mutations on VHL , a fraction of tumors still grows with the expression of wild‐type (WT) VHL and evolve into an aggressive subtype. Additionally, mutations on chromatin‐modifying genes, such as the gene coding for the histone methyltransferase SET containing domain 2 ( SETD2 ), are essential to ccRCC evolution. We previously identified STF‐62247, a small molecule first discovered as a synthetically lethal molecule for VHL ‐deficient cells by blocking late stages of autophagy. This study investigated how other commonly mutated genes in ccRCC could impact the response to STF‐62247. We showed that SETD2 inactivation in ccRCC cells expressing WT‐ VHL became vulnerable to STF‐62247, as indicated by decreases in cell proliferation and survival. Furthermore, activation of the DNA damage response pathway leads to the loss of M‐phase inducer phosphatase 1 (CDC25A) and cell cycle arrest in S phase. Cleavage of both caspase‐3 and gasdermin E suggests that STF‐62247 eliminates WT‐ VHL ccRCC cells through pyroptosis specifically when SETD2 is inactivated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellHistone-Lysine N-MethyltransferaseKidney NeoplasmsDNA DamageCell Cycle CheckpointsPyroptosisVon Hippel-Lindau Tumor Suppressor ProteinHumansCell Line, TumorCell Proliferation

Stichwörter der Autor:innen

PIKfyveSETD2STF‐62247clear cell renal cell carcinomapyroptosisvon Hippel–Lindau

Substanzen

Histone-Lysine N-MethyltransferaseSETD2 protein, humanVon Hippel-Lindau Tumor Suppressor ProteinVHL protein, human

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Université de Moncton, Canada.
  • Atlantic Cancer Research Institute, Moncton, Canada.

ORCID-Profile: Sandra Turcotte

Förderung

  • Fondation de la recherche en santé du Nouveau-Brunswick
  • New Brunswick Innovation Foundation
  • Canadian Cancer Society Research Institute

Zitieren

APA

Johnson, M., & Turcotte, S. (2025). Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF ‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis. Molecular Oncology. https://doi.org/10.1002/1878-0261.13770

Vancouver

Johnson M, Turcotte S. Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF ‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis. Molecular Oncology. 2025. doi:10.1002/1878-0261.13770

BibTeX
@article{Johnson2025,
  author = {Johnson, Mathieu and Turcotte, Sandra},
  title = {Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF ‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.13770}
}
Kostenlos starten →